Build Your Comparison

Side-by-side financial analysis
DOCS logo
DOCS
VEEV logo
VEEV
JPM logo
JPM
Try popular comparisons:

Stock Comparison

DOCS vs VEEV vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$3.75B
5Y Perf.-65.6%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$25.92B
5Y Perf.-48.7%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+106.2%

DOCS vs VEEV vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DOCS logoDOCS
VEEV logoVEEV
JPM logoJPM
IndustryMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesBanks - Diversified
Market Cap$3.75B$25.92B$896.00B
Revenue (TTM)$645M$3.32B$280.33B
Net Income (TTM)$196M$942M$57.05B
Gross Margin89.1%75.0%60.0%
Operating Margin33.3%28.8%25.9%
Forward P/E14.0x17.6x14.4x
Total Debt$10M$96M$942.38B
Cash & Equiv.$219M$1.42B$343.34B

DOCS vs VEEV vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DOCS
VEEV
JPM
StockJun 21Jun 26Return
Doximity, Inc. (DOCS)10034.4-65.6%
Veeva Systems Inc. (VEEV)10051.3-48.7%
JPMorgan Chase & Co. (JPM)100206.2+106.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: DOCS vs VEEV vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DOCS leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Veeva Systems Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇DOCS emerged as the overall leader. Track its performance:
DOCS
Doximity, Inc.
The Defensive Pick

DOCS has the current edge in this matchup, primarily because of its strength in sleep-well-at-night and valuation efficiency.

  • Lower volatility, beta 0.75, Low D/E 1.1%, current ratio 6.09x
  • PEG 0.27 vs VEEV's 0.97
  • Lower P/E (14.0x vs 17.6x), PEG 0.27 vs 0.97
Best for: sleep-well-at-night and valuation efficiency
VEEV
Veeva Systems Inc.
The Income Pick

VEEV is the clearest fit if your priority is income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 0.69
  • Rev growth 16.3%, EPS growth 25.9%, 3Y rev CAGR 14.0%
  • Beta 0.69, current ratio 4.89x
Best for: income & stability and growth exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding.

  • 465.8% 10Y total return vs VEEV's 367.2%
  • 1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
  • +21.8% vs DOCS's -64.8%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthVEEV logoVEEV16.3% revenue growth vs JPM's 3.3%
ValueDOCS logoDOCSLower P/E (14.0x vs 17.6x), PEG 0.27 vs 0.97
Quality / MarginsDOCS logoDOCS30.4% margin vs JPM's 20.4%
Stability / SafetyVEEV logoVEEVBeta 0.69 vs JPM's 0.94, lower leverage
DividendsJPM logoJPM1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)JPM logoJPM+21.8% vs DOCS's -64.8%
Efficiency (ROA)DOCS logoDOCS16.5% ROA vs JPM's 1.3%, ROIC 19.8% vs 4.5%

DOCS vs VEEV vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
DOCSDoximity, Inc.
FY 2026
Subscription
94.3%$608M
Service, Other
5.7%$36M
VEEVVeeva Systems Inc.
FY 2026
Subscription Services Veeva Commercial Cloud
86.9%$1.3B
Professional Services Veeva Commercial Cloud
13.1%$189M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

DOCS vs VEEV vs JPM — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGVEEV

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 434.7x DOCS's $645M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to JPM's 20.4%. On growth, VEEV holds the edge at +16.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$645M$3.3B$280.3B
EBITDAEarnings before interest/tax$227M$1.1B$81.4B
Net IncomeAfter-tax profit$196M$942M$57.0B
Free Cash FlowCash after capex$215M$518M$100.9B
Gross MarginGross profit ÷ Revenue+89.1%+75.0%+60.0%
Operating MarginEBIT ÷ Revenue+33.3%+28.8%+25.9%
Net MarginNet income ÷ Revenue+30.4%+28.4%+20.4%
FCF MarginFCF ÷ Revenue+33.3%+15.6%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+5.1%+16.3%
EPS Growth (YoY)Latest quarter vs prior year-67.7%+14.6%+16.0%
DOCS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 4 of 7 comparable metrics.

At 16.0x trailing earnings, JPM trades at a 45% valuation discount to VEEV's 29.3x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.39x vs VEEV's 1.61x — a lower PEG means you pay less per unit of expected earnings growth.

MetricDOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
Market CapShares × price$3.7B$25.9B$896.0B
Enterprise ValueMkt cap + debt − cash$3.5B$24.6B$1.50T
Trailing P/EPrice ÷ TTM EPS20.45x29.33x16.00x
Forward P/EPrice ÷ next-FY EPS est.13.99x17.61x14.40x
PEG RatioP/E ÷ EPS growth rate0.39x1.61x0.90x
EV / EBITDAEnterprise value multiple16.47x20.59x18.36x
Price / SalesMarket cap ÷ Revenue5.81x8.11x3.20x
Price / BookPrice ÷ Book value/share4.20x3.69x2.47x
Price / FCFMarket cap ÷ FCF18.70x8.88x
JPM leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

DOCS leads this category, winning 7 of 8 comparable metrics.

DOCS delivers a 19.4% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $13 for VEEV. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), DOCS scores 6/9 vs JPM's 5/9, reflecting solid financial health.

MetricDOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity+19.4%+13.4%+15.9%
ROA (TTM)Return on assets+16.5%+11.0%+1.3%
ROICReturn on invested capital+19.8%+12.9%+4.5%
ROCEReturn on capital employed+20.7%+13.8%+8.9%
Piotroski ScoreFundamental quality 0–9665
Debt / EquityFinancial leverage0.01x0.01x2.60x
Net DebtTotal debt minus cash-$209M-$1.3B$599.0B
Cash & Equiv.Liquid assets$219M$1.4B$343.3B
Total DebtShort + long-term debt$10M$96M$942.4B
Interest CoverageEBIT ÷ Interest expense0.74x
DOCS leads this category, winning 7 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $3,781 for DOCS. Over the past 12 months, JPM leads with a +21.8% total return vs DOCS's -64.8%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs DOCS's -15.0% — a key indicator of consistent wealth creation.

MetricDOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-53.7%-27.3%-0.5%
1-Year ReturnPast 12 months-64.8%-43.5%+21.8%
3-Year ReturnCumulative with dividends-38.7%-16.2%+138.2%
5-Year ReturnCumulative with dividends-62.2%-47.5%+118.2%
10-Year ReturnCumulative with dividends-62.2%+367.2%+465.8%
CAGR (3Y)Annualised 3-year return-15.0%-5.7%+33.6%
JPM leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — VEEV and JPM each lead in 1 of 2 comparable metrics.

VEEV is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than JPM's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs DOCS's 26.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5000.75x0.69x0.94x
52-Week HighHighest price in past year$76.51$310.50$337.25
52-Week LowLowest price in past year$17.16$148.05$262.71
% of 52W HighCurrent price vs 52-week peak+26.2%+51.4%+95.1%
RSI (14)Momentum oscillator 0–10040.743.859.1
Avg Volume (50D)Average daily shares traded3.9M2.3M7.0M
Evenly matched — VEEV and JPM each lead in 1 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 1 of 1 comparable metric.

Analyst consensus: DOCS as "Hold", VEEV as "Buy", JPM as "Buy". Consensus price targets imply 47.5% upside for VEEV (target: $235) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.

MetricDOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellHoldBuyBuy
Price TargetConsensus 12-month target$29.47$235.38$339.75
# AnalystsCovering analysts234361
Dividend YieldAnnual dividend ÷ price+1.9%
Dividend StreakConsecutive years of raises015
Dividend / ShareAnnual DPS$5.95
Buyback YieldShare repurchases ÷ mkt cap+11.5%+0.7%+3.9%
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway

JPM leads in 3 of 6 categories (Valuation Metrics, Total Returns). DOCS leads in 2 (Income & Cash Flow, Profitability & Efficiency). 1 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 3 of 6 categories
Loading custom metrics...

DOCS vs VEEV vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DOCS or VEEV or JPM a better buy right now?

For growth investors, Veeva Systems Inc.

(VEEV) is the stronger pick with 16. 3% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Veeva Systems Inc. (VEEV) a "Buy" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DOCS or VEEV or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Veeva Systems Inc. at 29. 3x. On forward P/E, Doximity, Inc. is actually cheaper at 14. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus Veeva Systems Inc. 's 0. 97x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — DOCS or VEEV or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -62. 2% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: JPM returned +465. 8% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DOCS or VEEV or JPM?

By beta (market sensitivity over 5 years), Veeva Systems Inc.

(VEEV) is the lower-risk stock at 0. 69β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 38% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — DOCS or VEEV or JPM?

By revenue growth (latest reported year), Veeva Systems Inc.

(VEEV) is pulling ahead at 16. 3% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Veeva Systems Inc. grew EPS 25. 9% year-over-year, compared to -11. 7% for Doximity, Inc.. Over a 3-year CAGR, DOCS leads at 15. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DOCS or VEEV or JPM?

Doximity, Inc.

(DOCS) is the more profitable company, earning 30. 4% net margin versus 20. 4% for JPMorgan Chase & Co. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus 26. 0% for JPM. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DOCS or VEEV or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus Veeva Systems Inc. 's 0. 97x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Doximity, Inc. (DOCS) trades at 14. 0x forward P/E versus 17. 6x for Veeva Systems Inc. — 3. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 47. 5% to $235. 38.

08

Which pays a better dividend — DOCS or VEEV or JPM?

In this comparison, JPM (1.

9% yield) pays a dividend. DOCS, VEEV do not pay a meaningful dividend and should not be held primarily for income.

09

Is DOCS or VEEV or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, DOCS: -62. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DOCS and VEEV and JPM?

These companies operate in different sectors (DOCS (Healthcare) and VEEV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DOCS is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while DOCS, VEEV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.